IIM
ENTA icon

INTECH Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

INTECH Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,101
Closed -$83.9K – 2436
2025
Q2 		$83.9K Sell
11,101
-6,029
-35% -$36.3K ﹤0.01% 2333
2025
Q1 		$94.6K Buy
17,130
+7,038
+70% +$43.5K ﹤0.01% 2325
2024
Q4 		$58K Buy
+10,092
New +$96.8K ﹤0.01% 2313

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

INTECH Investment Management's ENTA Position: Q3 2025 in Review

INTECH Investment Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2025, closing a stake of 11,101 shares — an estimated $83.9K sold.

INTECH Investment Management first reported a position in ENTA in Q4 2024 and held it in 3 quarters. The position peaked at $94.6K in Q1 2025. 121 funds tracked by Wall St. Rank hold ENTA as of Q3 2025.

  • INTECH Investment Management reported no remaining Enanta Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • INTECH Investment Management sold 11,101 Enanta Pharmaceuticals shares in Q3 2025, an estimated $83.9K.
  • INTECH Investment Management first reported a position in Enanta Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • INTECH Investment Management's Enanta Pharmaceuticals position peaked at $94.6K in Q1 2025.
  • 121 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2025.

Based on INTECH Investment Management's 13F filing for Q3 2025, filed 12 Nov 2025.